Goldman Sachs recently hosted the "Healthcare CEOs Unscripted" conference, and our health care analyst Max Macaluso was particularly interested in the interview with Merck's (NYSE: MRK ) CEO, Kenneth Frazier. Max discusses the three takeaways he thought were most important from the talk -- including Merck's business strategy compared to the high profile spinouts recently engineered by Abbott (NYSE: ABT ) and Pfizer (NYSE: PFE ) -- and also offers his 2013 outlook for Merck.
Merck was on course to record an impressive 2012, but a poor finish at the end of the year resulted in muted returns for investors. If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market.
How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.